[{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Orders More Rabeximod Substance and Confirms Timeline for the Phase IIb Program","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Professor Rikard Holmdahl","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyxone Signs Agreement With Professor Rikard Holmdahl as Senior Scientific Advisor","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Plans to Initiate a Phase 2 Clinical Trial with Rabeximod in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Revises the Development Plan for Rabeximod","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Files Patent Application to Extend Exclusivity of Rabeximod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Receives Regulatory Approval to Initiate a Clinical Phase 2 Study with Rabeximod in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone has Filed an IND in the US with Rabeximod Following Positive Feed-Back from Pre-Ind Meeting with the FDA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Cyxone AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"World Leading Rheumatology Authority Professor Costantino Pitzalis Collaborates with Cyxone on Rabeximod Phase 2b Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cyxone Will Leverage IND and Use FDA Pre-Review for Covid-19 Phase 2 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Cyxone AB
While Cyxone continues to develop the oral administration form for T20K, the company has also decided to initiate a feasibility study on a subcutaneous administration form in Q2 2021. Finally, biomarker development to support both administration forms will be completed.
Professor Pitzalis will be pivotal in Cyxone’s planned clinical trial in RA indication for the compound Rabeximod. Professor Pitzalis along with a team of world-class international rheumatologists has advised Cyxone on the updated Phase 2b trial design.
The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery.
The IND covers the development of Rabeximod in Covid-19 and other indications, such as rheumatoid arthritis, and is a prerequisite for a future validation of the company’s five recent patent applications in the US market.
Cyxone has received approval from the regulatory authority and the ethics committee in Poland to initiate a Phase 2 clinical trial with Rabeximod in moderate Covid-19 patients.
New patent applications have been filed to extend exclusivity on Rabeximod, potentially to 2043. A patent application related to Covid-19 has also been filed.
Cyxone plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 patients. The treatment is intended to reduce the risk of developing severe respiratory symptoms caused by virus-related overactivation of the immune system.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
